NCT02475486View on ClinicalTrials.gov

Role of the ANS Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 25, 2016

Primary Completion Date

October 8, 2018

Study Completion Date

October 8, 2018

Conditions
Rheumatoid Arthritis
Interventions
DEVICE

VistaO2

ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients

Trial Locations (1)

42055

Chu Saint-Etienne, Saint-Etienne

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT02475486 - Role of the ANS Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF | Biotech Hunter | Biotech Hunter